semaglutide (oral)
peptide · Novo Nordisk A/S · Metabolic glp1
Current state
- Status
- Phase 3 — 0 active of 2 tracked studies
- Sponsor
- Novo Nordisk A/S
- Modality
- peptide
- Mechanism
- GLP-1 receptor agonist
- Thesis
- Metabolic glp1
- Record checked
- Verified by a curator
- Last change
- no change event observed since tracking began
- Last reviewed
- (today)
Trials — 2
| NCT | Title | Phase | Status | Start | Primary completion | N | APOE-strat. |
|---|---|---|---|---|---|---|---|
| NCT04777396 | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) | PHASE3 | COMPLETED | 1840 | no | ||
| NCT04777409 | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | PHASE3 | COMPLETED | 1840 | no |
Publications — 0
No linked publication. Nothing has been resolved to this therapeutic in Europe PMC or OpenAlex. Where nobody has checked the record yet, this usually means the identifier is used inconsistently in the literature rather than that no work exists.
Change history — 0
No changes detected for semaglutide (oral) as of the snapshot taken .
This is not the same as nothing having happened. The oldest source in this snapshot last succeeded (2 days ago), and registry and filing data lag the events they describe. See methodology.